Menten AI
Pioneering Generative AI for Peptide Drug Design
Menten AI develops MAUD 1.0, a generative AI platform for de novo peptide macrocycle drug design targeting complex protein-protein interfaces. The platform combines generative AI with physics-based models and quantum simulations to accelerate preclinical drug discovery. It is trusted by top-10 pharma partners and backed by leading venture capital firms.
MAUD 1.0 uses generative AI combined with physics-based models and quantum simulations to design and optimize drug-like peptide macrocycles de novo from scratch.
pharmaceutical researchers and drug discovery teams
Background.
- Status
- launched
- Business model
- unknown
- Company
- Menten AI
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.